Biomarin Pharmaceutical Inc. BMRN

NAS: BMRN | ISIN: US09061G1013   17/10/2025
53,29 USD (+0,64%)
(+0,64%)   17/10/2025

8 september 2025 · BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting · Persbericht

6 september 2025 · BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism · Persbericht

27 augustus 2025 · BioMarin to Participate in Upcoming Investor Conferences · Persbericht

4 augustus 2025 · BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS · Persbericht

1 augustus 2025 · BioMarin Announces Appointment of Ian T. Clark to Board of Directors · Persbericht

22 juli 2025 · BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET · Persbericht

1 juli 2025 · BioMarin Announces Completion of Acquisition of Inozyme · Persbericht

24 juni 2025 · BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress · Persbericht

16 mei 2025 · BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma · Persbericht

12 mei 2025 · BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings · Persbericht

1 mei 2025 · BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance · Persbericht

17 april 2025 · BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET · Persbericht

2 april 2025 · BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria · Persbericht

20 maart 2025 · BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting · Persbericht

4 september 2024 · BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance · Persbericht

4 september 2024 · BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time · Persbericht

29 augustus 2024 · BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY · Persbericht

21 augustus 2024 · BioMarin Announces New R&D and Business Development Leadership · Persbericht

19 augustus 2024 · BioMarin to Host 2024 Investor Day on September 4th in New York · Persbericht

5 augustus 2024 · BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance · Persbericht

Mijn selecties